Sickle Cell Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.32 Billion |
| Market Size (2029) | USD 6.11 Billion |
| CAGR (2024 - 2029) | 12.98 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Sickle Cell Treatment Market Analysis
The Sickle Cell Treatment Market size is estimated at USD 3.32 billion in 2024, and is expected to reach USD 6.11 billion by 2029, growing at a CAGR of 12.98% during the forecast period (2024-2029).
The impact of the COVID-19 pandemic on the studied market was significant. For instance, according to the data updated by the American Society of Hematology in May 2021, it was stated that CDC has designated sickle cell disease (SCD) as one of the medical conditions with a very high risk for severe COVID-19. Thus, the COVID-19 pandemic significantly impacted the market's growth during the initial phase. However, as the pandemic has currently subsided, the market is expected to have normal growth during the forecast period.
Factors such as the increasing prevalence of sickle cell disease and the increasing R&D activities regarding sickle cell disease are expected to boost the market's growth.
According to an article published by HemaSphere in June 2022, sickle cell disease (SCD) is said to have a high prevalence and social impact worldwide, with high mortality within the first three years of life. A high prevalence of the disease has been reported in Sub-Saharan Africa, the Mediterranean, the Middle East, and India. It has also been estimated that the prevalence is increasing in other geographic regions with global migration. Thus, the rising prevalence of sickle cell disease is expected to boost the market's growth during the forecast period.
The rising initiatives by various governments and private organizations for the treatment of this disease are expected to drive the market in the coming years. For instance, according to the data published by the WHO in August 2022, a few African health ministers launched a campaign to ramp up awareness and bolster prevention and care to reduce the toll of sickle cell disease, which is one of the most common illnesses in the region, but which receives inadequate attention. The source also stated that more than 66% of the 120 million people affected worldwide by sickle cell disease live in Africa. Approximately 1,000 children are born with the disease every day in Africa, making it the region's most prevalent genetically acquired disease. Thus, the high prevalence of sickle cell disease and the increasing awareness campaigns for the treatment of this disease are some of the key market drivers.
The increasing R&D for sickle cell disease may also drive the market. For instance, in May 2022, multiple daily doses of GBT601, Global Blood Therapeutics' (GBT) experimental oral therapy for sickle cell disease (SCD), was well tolerated and showed promising pharmacological and efficacy signals in six patients in a phase I trial clinical trial.
Thus, factors such as the rising prevalence of sickle cell disease, the increasing awareness campaigns, and the rising R&D are expected to boost the market's growth. However, the high cost of treatment is expected to restrain this growth.
Sickle Cell Treatment Market Trends
Blood Transfusion Segment is Expected to Witness Significant Growth Over the Forecast Period
The blood transfusion segment is expected to witness healthy growth over the forecast period. The growth of this segment is attributed to the high demand for blood transfusion in sickle cell treatment and the increase in the prevalence of SCD. Blood transfusions enable the supply of normal red blood cells, which can enhance hemoglobin levels to improve oxygen delivery in the body, thereby reducing sickle cell blockage in blood vessels and minimizing the desire to make more sickle cells.
The rising prevalence of sickle cell disease is the major factor driving the segment's growth. According to an article published by HemaSphere in August 2022, a study in India showed a very high prevalence of sickle cell disease among the non-tribal people in Chattisgarh, India. Thus, the rising prevalence of sickle cell disease is expected to drive the segment during the forecast period.
The increasing usage of blood transfusion to manage the disease is also expected to impact the segment positively. For instance, according to the data updated by CDC in September 2021, if a person has sickle cell disease (SCD), then one or more blood transfusions (healthy blood from a donor put into your body) are required during the lifetime. During a blood transfusion, the patient's blood and the donated blood must have matching antigens or special proteins on the surface of each red blood cell.
The rising R&D for sickle cell disease is also expected to boost the segment's growth. For instance, according to the data updated by clinicaltrials.gov in February 2023, currently, there are 58 ongoing and active clinical trials for blood transfusion in sickle cell disease. Thus, the large number of clinical trials is expected to boost the adoption of blood transfusion for this treatment.
Thus, factors such as the rising prevalence of sickle cell disease, the increasing usage of blood transfusion for the management of the disease, and the rising R&D for sickle cell disease are expected to enhance the segment's growth.
North America is Expected to Hold a Significant Share in the Sickle Cell Treatment Market During the Forecast Period
North America is expected to hold a significant share of the overall sickle cell treatment market, with the United States being the major contributor. The growth in the region is attributed to improving access to SCD treatment and potential pipeline candidates. The strong government support in the United States will further foster the market's development. The rising prevalence of sickle cell disease in the region, the increasing number of clinical trials, and the rising product launches are expected to boost the market's growth in the region.
According to the data updated by CDC in May 2022, sickle cell disease (SCD) affects approximately 100,000 Americans every year, and SCD occurs among about 1 out of every 365 black or African American births. The source also stated that SCD occurs among about 1 out of every 16,300 Hispanic American births, and about 1 in 13 black or African-American babies is born with sickle cell trait (SCT). Similarly, according to an article published by the Canadian Pediatric Society in February 2022, sickle cell disease (SCD) is considered one of the most common human genetic diseases, and it affects at least 5,000 individuals in Canada every year.
The increasing initiatives by the government are also expected to boost the market's growth in the region. For instance, in September 2022, the National Institutes of Health (NIH) granted a five-year, USD 7.7 million grant to support a new research project that seeks to lower barriers to healthcare for people with sickle cell disease (SCD).
The increasing developments by key market players are also expected to boost the market's growth. For instance, in May 2022, the US FDA awarded fast-track designation to Graphite Bio's GPH101. This investigational gene-editing therapy aims to correct the genetic mutation that causes sickle cell disease (SCD) and potentially cure the condition. In January 2022, Agios Pharmaceuticals launched a phase 2/3 trial called RISE UP to test its investigational therapy mitapivat (AG-348) in people with sickle cell disease (SCD).
Thus, factors such as the rising prevalence of sickle cell disease and the rising R&D are expected to boost the market's growth in the region.
Sickle Cell Treatment Industry Overview
The sickle cell treatment market is highly competitive, with the presence of several regional and global companies. Companies are taking initiatives to develop novel therapies in the market studied. Some of the players include Novartis AG, Global Blood Therapeutics Inc., Emmaus Medical Inc., Addmedica, Medunik USA Inc., and Bristol-Myers Squibb Company.
Sickle Cell Treatment Market Leaders
-
Novartis AG
-
Emmaus Medical Inc.
-
Addmedica
-
Medunik USA Inc.
-
Global Blood Therapeutics Inc
*Disclaimer: Major Players sorted in no particular order
Sickle Cell Treatment Market News
- In December 2022, Bluebird Bio Inc. announced that the US FDA had lifted a partial clinical hold on studies for its gene therapy to treat the blood disorder sickle cell disease.
- In February 2022, Global Blood Therapeutics Inc. received marketing authorization for Oxbryta to treat hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
Sickle Cell Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Sickle Cell Disease
- 4.2.2 Increasing R&D Activity
-
4.3 Market Restraints
- 4.3.1 High Cost of Treatment
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Treatment Modality
- 5.1.1 Blood Transfusion
- 5.1.2 Bone Marrow Transplant
- 5.1.3 Pharmacotherapy
-
5.2 By End User
- 5.2.1 Hospitals
- 5.2.2 Specialty Clinics
- 5.2.3 Other End Users
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Novartis AG
- 6.1.2 Global Blood Therapeutics Inc.
- 6.1.3 Emmaus Medical Inc.
- 6.1.4 Addmedica
- 6.1.5 Medunik USA
- 6.1.6 Bristol Myers Squibb Co.
- 6.1.7 Sanofi SA
- 6.1.8 Bluebird Biotechnology
- 6.1.9 Pfizer Inc.
- 6.1.10 Aruvant Sciences Inc.
- 6.1.11 Glycomimetics Inc.
- 6.1.12 Editas Medicine Inc.
- 6.1.13 CRISPR Therapeutic
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablitySickle Cell Treatment Industry Segmentation
As per the scope of the report, sickle cell is a group of disorders that cause red blood cells to become misshapen and break down. With sickle cell disease, an inherited group of disorders, red blood cells contort into a sickle shape. The cells die early, leaving a shortage of healthy red blood cells (sickle cell anemia), and can block blood flow, causing pain (sickle cell crisis).
The sickle cell treatment market is segmented by treatment modality (bone marrow transplant, blood transfusion, and pharmacotherapy), end user (hospitals, specialty clinics, and other end users), geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment Modality | Blood Transfusion | |
| Bone Marrow Transplant | ||
| Pharmacotherapy | ||
| By End User | Hospitals | |
| Specialty Clinics | ||
| Other End Users | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Sickle Cell Treatment Market Research FAQs
How big is the Sickle Cell Treatment Market?
The Sickle Cell Treatment Market size is expected to reach USD 3.32 billion in 2024 and grow at a CAGR of 12.98% to reach USD 6.11 billion by 2029.
What is the current Sickle Cell Treatment Market size?
In 2024, the Sickle Cell Treatment Market size is expected to reach USD 3.32 billion.
Who are the key players in Sickle Cell Treatment Market?
Novartis AG, Emmaus Medical Inc., Addmedica, Medunik USA Inc. and Global Blood Therapeutics Inc are the major companies operating in the Sickle Cell Treatment Market.
Which is the fastest growing region in Sickle Cell Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Sickle Cell Treatment Market?
In 2024, the North America accounts for the largest market share in Sickle Cell Treatment Market.
What years does this Sickle Cell Treatment Market cover, and what was the market size in 2023?
In 2023, the Sickle Cell Treatment Market size was estimated at USD 2.94 billion. The report covers the Sickle Cell Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Sickle Cell Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Sickle Cell Treatment Industry Report
Statistics for the 2024 Sickle Cell Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Sickle Cell Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
